Patents Examined by Sean E Aeder
  • Nucleic acid and corresponding protein entitled 125P5C8 useful in treatment and detection of cancer
    Patent number: 7928196
    Abstract: A novel gene (designated 125P5C8) and its encoded protein, and variants thereof, are described wherein 125P5C8 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 125P5C8 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 125P5C8 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 125P5C8 can be used in active or passive immunization.
    Type: Grant
    Filed: June 21, 2010
    Date of Patent: April 19, 2011
    Assignee: Agensys, Inc.
    Inventors: Mary Faris, Pia M. Challita-Eid, Rene S. Hubert, Daniel E. H. Afar, Arthur B. Raitano, Wangmao Ge, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Aya Jakobovits
  • Treatment for CD5 B cell lymphoma
    Patent number: 7923429
    Abstract: The present invention provides methods for increasing expression of cell surface molecules of CD5+ B cell lymphoma cells by contacting cells with immune response modifiers. The invention also provides methods for the treatment of CD5+ B cell lymphomas, including chronic lymphocytic leukemia and small lymphocytic lymphoma, by administering immune response modifier compounds to a subject in need of such treatment. Suitable immune response modifier compounds include agonists of TLR7 and/or TLR8.
    Type: Grant
    Filed: July 15, 2008
    Date of Patent: April 12, 2011
    Assignee: 3M Innovative Properties Company
    Inventors: Richard L. Miller, David E. Spaner
  • Methods for predicting treatment response based on the expression profiles of protein and transcription biomarkers
    Patent number: 7919261
    Abstract: The invention disclosed herein describes novel biomarkers useful for risk assessment, screening, prognosis and selection and monitoring of therapy for HDAC mediated cell proliferative disorders. In particular, the invention provides the identities of three particular proteins whose expression patterns are strongly predictive of a particular patient's treatment outcome, e.g., non-responsiveness to SAHA. The expression profile, or pattern, whether embodied in nucleic acid expression, protein expression, or other expression formats will find use in identifying and selecting patients afflicted with a particular HDAC mediated cancer who are likely to be non-responsive to SAHA-based therapy and thus candidates for other treatments.
    Type: Grant
    Filed: December 1, 2006
    Date of Patent: April 5, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Valeria R. Fantin, Jacqueline W. Pierce, Andrey Loboda
  • Means for the diagnosis and therapy of CTCL
    Patent number: 7919085
    Abstract: The invention relates to a novel molecule, termed SC5 by the inventors, to a novel allelic form of p140, and to the biological applications of SC5 and p140 molecules, notably in the diagnosis and therapy of CTCL.
    Type: Grant
    Filed: March 18, 2008
    Date of Patent: April 5, 2011
    Assignee: Institut National de la Sante et de la Recherche Medicale
    Inventors: Armand Bensussan, Martine Bagot, Laurence Boumsell, Allessandro Moretta
  • SEMA4D in cancer diagnosis, detection and treatment
    Patent number: 7919246
    Abstract: This invention is in the field of cancer-related genes. Specifically it relates to methods for detecting cancer or the likelihood of developing cancer based on the presence or absence of the SEM A4D gene or proteins encoded by this gene. The invention also provides methods and molecules for upregulating or downregulating the SEMA4D gene.
    Type: Grant
    Filed: April 7, 2006
    Date of Patent: April 5, 2011
    Assignees: Novartis Vaccines and Diagnostics, Inc., Sagres Discovery, Inc.
    Inventors: Albert Lai, Abdallah Fanidi, Robert Booher, Christin Tse, Xie Xu, Guoying Yu, Edward Moler, Michael Rowe
  • Kit and method for detecting urothelial cancer
    Patent number: 7910316
    Abstract: This invention relates to a method for detecting in vitro a urothelial cancer, comprising measuring CXCL1 protein, or expression of a gene encoding the protein, in a biological sample from a subject, and to a kit for diagnosing a urothelial cancer comprising an antibody or nucleic acid probe, which is capable of binding specifically to the CXCL1 protein or a gene encoding the protein, respectively.
    Type: Grant
    Filed: September 1, 2006
    Date of Patent: March 22, 2011
    Assignees: Toray Industries, Inc., Kyoto University
    Inventors: Hideo Akiyama, Yoshinori Tanaka, Satoko Kozono, Hitoshi Nobumasa, Osamu Ogawa, Takeshi Takahashi
  • Detection of micro metastasis of melanoma and breast cancer in paraffin-embedded tumor draining lymph nodes by multimarker quantitative RT-PCR
    Patent number: 7910295
    Abstract: The invention provides a quantitative realtime RT-PCR assay for detection of metastatic breast, gastric, pancreas or colon cancer cells or metastatic melanoma. The assay allows to predict disease recurrence and survival in patients with AJCC stage I and II, and III disease using multimarker panels. The method for detecting metastatic melanoma cells utilizes panels of markers selected from a group consisting of MAGE-A3, GalNAcT, MART-1, PAX3, Mitf, TRP-2, and Tyrosinase. The method for detecting metastatic breast, gastric, pancreas or colon cancer cells in paraffin-embedded samples utilizes panels of markers selected from a group consisting of C-Met, MAGE-A3, Stanniocalcin-1, mammoglobin, HSP27, GalNAcT, CK20, and ?-HCG.
    Type: Grant
    Filed: November 14, 2003
    Date of Patent: March 22, 2011
    Assignee: John Wayne Cancer Institute
    Inventors: Dave S. B. Hoon, Hiroya Takeuchi
  • Methods of diagnosing ovarian cancer and kits therefor
    Patent number: 7910318
    Abstract: A method comprising: providing a biological sample from a subject (subject sample); and detecting the expression level of each of the markers FGF-2 and CA125 in the subject sample. A kit comprising means for detection of an expression level of each of markers CA125 and FGF-2 in a biological sample from a subject (subject sample), and instructions to use said markers in a method of the present invention.
    Type: Grant
    Filed: September 15, 2006
    Date of Patent: March 22, 2011
    Assignees: The Royal Institution for the Advancement of Learning/McGill University, Val-Chum, S.E.C.
    Inventors: Cecile LePage, Anne-Marie Mes-Masson, Diane Provencher, Patricia Tonin, Thomas Hudson
  • Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of ovarian cancer
    Patent number: 7906635
    Abstract: Novel markers for ovarian cancer that are both sensitive and accurate. These markers are overexpressed and/or differentially expressed in ovarian cancer specifically, as opposed to normal ovarian tissue. The measurement of these markers, alone or in combination, in patient samples provides information that the diagnostician can correlate with a probable diagnosis, in ovarian cancer. The markers of the present invention, alone or in combination, show a high degree of differential detection between ovarian cancer and non-cancerous states.
    Type: Grant
    Filed: January 15, 2009
    Date of Patent: March 15, 2011
    Assignee: Compugen Ltd.
    Inventors: Gad S. Cojocaru, Sarah Pollock, Zurit Levine, Alexander Diber, Guy Kol, Amir Toporik, Rotem Sorek, Dvir Dahary, Michal Ayalon-Soffer, Pinchas Akiva, Amit Novik, Yossi Cohen, Osnat Sella-Tavor, Shira Walach, Shirley Sameah-Greenwald, Ronen Shemesh, Maxim Shklar
  • Anti-tumor drug, medicament, composition, and use thereof
    Patent number: 7906621
    Abstract: An active polypeptide includes the amino acid sequence of SEQ ID NO:3, or having at least 50%, preferably 70%, more preferably 90% identity with the amino acid sequence of SEQ ID NO:3, or fragments thereof having at least 20 contiguous amino acids, or peptides having at least 50%, preferably 70%, more preferably 90% identity with the amino acid sequence of the fragments, provided that the polypeptide is not SEQ ID NO:2.
    Type: Grant
    Filed: May 16, 2007
    Date of Patent: March 15, 2011
    Assignee: Gene Signal International SA
    Inventors: Sylvie Colin, Salman Al-Mahmood
  • Diagnostic tool for diagnosing benign versus malignant thyroid lesions
    Patent number: 7901881
    Abstract: The present invention relates to the use of genes differentially expressed in benign thyroid lesions and malignant thyroid lesions for the diagnosis and staging of thyroid cancer.
    Type: Grant
    Filed: April 11, 2005
    Date of Patent: March 8, 2011
    Assignees: The United States of America as represented by the Department of Health and Human Services, The John Hopkins University
    Inventors: Steven K. Libutti, Chiara Mazzanti, Martha Zeiger, Christopher Umbricht
  • Screening assays for antioxidants and antiproliferative compounds
    Patent number: 7901878
    Abstract: Provided are screening assays for identifying and evaluating compounds with antioxidant and/or antiproliferative activities.
    Type: Grant
    Filed: December 8, 2008
    Date of Patent: March 8, 2011
    Assignee: University of Massachusetts
    Inventor: Robert E Carraway
  • Cell cycle phase markers
    Patent number: 7897741
    Abstract: The present invention relates to polypeptide and nucleic acids constructs which are useful for determining the cell cycle status of a mammalian cell. Host cells transfected with these nucleic acid constructs can be used to determine the effects that test agents have upon the mammalian cell cycle.
    Type: Grant
    Filed: September 16, 2009
    Date of Patent: March 1, 2011
    Assignee: GE Healthcare UK Limited
    Inventors: Suzanne Hancock, Simon Stubbs, Nicholas Thomas, Ellen Fanning, Jinming Gu
  • Methods and systems of using exosomes for determining phenotypes
    Patent number: 7897356
    Abstract: Exosomes can be used for detecting biomarkers for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, for example, the stage or progression of a disease. Cell-of-origin exosomes can be used in profiling of physiological states or determining phenotypes. Biomarkers or markers from cell-of-origin specific exosomes can be used to determine treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. Markers from cell-of-origin specific exosomes can also be used to identify conditions of diseases of unknown origin.
    Type: Grant
    Filed: November 12, 2009
    Date of Patent: March 1, 2011
    Assignee: Caris Life Sciences
    Inventors: Michael Klass, Christine Kuslich, George Poste
  • Secreted protein called 36P6D5 characteristic of tumors
    Patent number: 7897740
    Abstract: Described is a gene and its encoded secreted tumor antigen, termed 36P6D5, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers which express 36P6D5, particularly including cancers of the bladder, kidney, prostate, breast, colon, ovary, and pancreas.
    Type: Grant
    Filed: February 26, 2009
    Date of Patent: March 1, 2011
    Assignee: Agensys, Inc.
    Inventors: Arthur B. Raitano, Aya Jakobovits, Mary Faris, Daniel E. H. Afar, Rene S. Hubert, Steve Chappell Mitchell
  • Use of N-myristoyltransferase on non-tumor tissue for cancer diagnosis
    Patent number: 7892758
    Abstract: A diagnostic method and kit are disclosed for detection of cancer. Detection of elevated levels of N-myristoyltransferase (NMT) or NMT activity in blood or bone marrow, and specifically in peripheral blood mononuclear cells, can be used as a marker for cancer. The use of this method for detection of adenocarcinoma, such as colorectal cancer, is exemplified.
    Type: Grant
    Filed: September 26, 2006
    Date of Patent: February 22, 2011
    Assignee: University of Saskatchewan
    Inventors: Rajendra Kumar Sharma, Anuraag Shrivastav
  • Pot1 alternative splicing variants
    Patent number: 7892738
    Abstract: The present invention provides methods an compositions for diagnosis and treatment of carcinomas with aberrant expression patterns of POT 1. The invention also provides methods of identifying compounds that may modulate the cellular expression of POT 1. The invention further provides methods for treating subjects suffering from or at risk of developing a colorectal carcinoma.
    Type: Grant
    Filed: October 19, 2005
    Date of Patent: February 22, 2011
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Qin Yang, Curtis C. Harris
  • Prognosis and therapy predictive markers and methods of use
    Patent number: 7892740
    Abstract: Disclosed is a set of genes differentially expressed in chemotherapy and radiation resistant tumors useful in predicting response to therapy and assessing risk of local-regional failure, survival and metastasis in cancer patients. Also disclosed are methods for characterizing tumors according to gene expression and kits for use in the methods of the invention.
    Type: Grant
    Filed: January 19, 2007
    Date of Patent: February 22, 2011
    Assignee: The University of Chicago
    Inventors: Ralph Weichselbaum, Bernard Roizman, Andy Minn, Nikolai Khodarev, Edwardine Labay
  • Lung cancer markers, and uses thereof
    Patent number: 7892760
    Abstract: Methods and compositions are provided for assessing (e.g., diagnosing), treating, and preventing diseases, especially cancer, and particular lung cancer, using lung cancer markers (LCM). Individual LCM and panels comprising multiple LCM are provided for these and other uses. Methods and compositions are also provided for determining or predicting the effectiveness of a treatment or for selecting a treatment using LCM. Methods and compositions are further provided for modulating cell function using LCM. Also provided are compositions that modulate LCM (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate LCM, and agents identified by these screening methods.
    Type: Grant
    Filed: November 19, 2008
    Date of Patent: February 22, 2011
    Assignee: Celera Corporation
    Inventors: Charles Birse, Marcia Lewis, Steve Ruben, Mehdi Mesri
  • Protein markers for diagnosing stomach cancer and the diagnostic kit using them
    Patent number: 7892761
    Abstract: The present invention relates to protein markers for diagnosing stomach cancer and a diagnostic kit using the same, more precisely protein markers screened by two-dimensional gel electrophoresis and bioinformatics and a diagnostic kit using the same. The markers of the invention can be effectively used for diagnosing stomach cancer and evaluating the extent of progress of the cancer by confirming the expression levels of those marker proteins whose expressions differ in stomach cancer patients from in normal healthy people.
    Type: Grant
    Filed: December 28, 2006
    Date of Patent: February 22, 2011
    Assignee: Bioinfra Inc.
    Inventors: Chul Woo Kim, Syng-Yup Ohn, Mi Young Han, Yong-Sung Shin